The goal of this RPP is to develop prototypes aimed to treat COVID-19 with the following focus area: Therapeutic(s) that can treat COVID-19. Treatments with potential application to the prevention of COVID-19 infection are desired. Therapeutics that can be administered in a non-hospital environment are desired. *Note: Pending successful completion of this effort, the Government may issue a noncompetitive follow-on production contract or transaction pursuant to 10 USC 2371b section f.
The U.S. Government (USG) Department of Defense (DoD) currently has available approximately $20 Million (M) of FY20 funds. Any potential follow-on funding is expected to be awarded noncompetitively and negotiated based on outcomes, cost sharing, partner matching and estimates for additional study completion.
The goal of this RPP is to develop prototype countermeasures for the treatment of COVID-19.
The Offeror is expected to have at the onset a candidate therapeutic with non-clinical data (in vitro, tox, pre-clinical data, etc.) suggesting safety and/or efficacy.
- The expected TRL at start of the POP is 3/4 and at the end of the POP is TRL6
- The Offeror is expected to have at the onset a candidate therapeutic with non-clinical data (in vitro, tox, pre-clinical data, etc.) suggesting safety and/or efficacy
- The Offeror should have demonstrated manufacturing feasibility of the candidate therapeutic
- Offerors who have had at least one meeting with the FDA to discuss the regulatory strategy for their candidate(s) are preferred
- Repurposing commercially available, approved products or products in clinical development for related indications with demonstrated safety in humans are preferred
- Partnering with DoD investigators on pre-clinical testing in animal models is encouraged, where appropriate. [Note: Relationships with DoD laboratories must be brought forth as part of the Enhanced White Paper. MTEC members can access points of contact at Army laboratories on the members-only website.
The MTEC will use an accelerated approach to award for this RPP. Because of the nature and urgency of the requirements set forth in this RPP, this streamlined approach is anticipated to be a better means to highlight company methodologies and skills required to address the technical requirements described herein. The Enhanced White Paper process requires extremely quick turnaround times by Offerors.
Request Issue Date: March 25, 2020
Enhanced White Paper Due Date: April 8, 2020 Noon Eastern Time Zone
URL for more information:
Filed Under: Funding Opportunities